Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

TASKEEN MUJTABA, JYOTI KANWAR, SHENG BIAO WAN, TAK HANG CHAN and Q. PING DOU

1The Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, MI, USA; 2Department of Applied Biology and Chemistry, The Polytechnic University of Hong Kong, Hung Hum, Hong Kong SAR, P.R. China; 3Department of Chemistry, McGill University, Montreal, Quebec H3A 2K6, Canada

Received August 9, 2011; Accepted September 8, 2011

DOI: 10.3892/ijmm.2011.814

Abstract. The proteasome plays a vital role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis and is a validated target in cancer treatment. Bortezomib (Velcade®, PS-341) is the first US FDA approved proteasome inhibitor anticancer drug used in the treatment of refractory multiple myeloma. In spite of its improved efficacy compared to alternative therapies, about 60% of patients do not respond to bortezomib due to the emergence of resistance. We hypothesized that novel small molecules could enhance the proteasome-inhibitory and anticancer activities of bortezomib in resistant multiple myeloma cells in vitro and in vivo. The dietary polyphenol curcumin has been shown to exert anti-cancer activity in several cancer cell lines, but the effects of curcumin in solid tumors have been modest primarily due to poor water solubility and poor bioavailability in tissues remote from the gastrointestinal tract. Here we show that the water-soluble analog of curcumin #12, but not curcumin, in combination with bortezomib could enhance the proteasome-inhibitory effect in multiple myeloma cells. Furthermore, the sensitivity of the myeloma cells to cytotoxic killing in the presence of otherwise sublethal concentrations of bortezomib was enhanced by incubation with the curcumin analog #12. These findings justify further investigation into those combinations that may yield potential therapeutic benefit.

Introduction

Multiple myeloma (MM) is a neoplasm of mature clonal B cells and is the second most common hematological malignancy after non-Hodgkin's lymphoma. It accounts for approximately 15% of all lymphohematopoietic cancers. Incidence of MM increases with age and its rate of occurrence is higher in men. Despite the availability of new drugs MM still remains an incurable disease. Current cancer therapies are intended to selectively target specific biomarkers that are altered in the malignant phenotype to dampen tumor progression, which is limited by many factors. Alternatively, targeting the proteasome, which regulates multiple cellular events, represents one of the most successful anticancer strategies.

Bortezomib (Velcade®, PS-341) is the first US food and drug administration (FDA) approved proteasome inhibitor. It has shown remarkable success in the treatment of hematological malignancies, however about 60% of patients do not respond to bortezomib due to the emergence of resistance. Some of the molecular mechanisms for resistance have been found to be the overexpression of the β5 subunit of the proteasome (1) overexpression of the anti-apoptosis protein Bcl-2 (2), and high secretion of GRP-78, a chaperone protein of the unfolded protein response (3). In B-cell lymphomas overexpression of heat shock protein (HSP)27, HSP70, HSP90 and T-cell factor 4 is associated with bortezomib resistance (4). In solid tumor cell lines (lung, cervical and colon) bortezomib treatment had minimal effects as it induced the formation of stress granules (5). Proteasome inhibitor-resistant constitutive activation of NF-κB has also been reported (6). Targeting these resistance mechanisms could therefore increase the efficacy of proteasome inhibition by bortezomib. Another potential limitation of bortezomib therapy is its interaction with several natural products including polyphenols containing vicinal diols that block its activity (7). Overcoming these challenges requires identification of mechanisms that confer sensitivity to proteasome inhibition and identification of a novel class of agents, which can be safely used in combination with bortezomib.

A potential prospect is to use natural compounds that do not interact with bortezomib to sensitize tumors to bortezomib therapy. Several naturally occurring products have great

Correspondence to: Dr Q.P. Dou, The Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, School of Medicine, Wayne State University, 540.1 HWCRC, 4100 John R Road, Detroit, MI 48201-2013, USA
E-mail: dou@karmanos.org

Dr T.H. Chan, Department of Chemistry, McGill University, Montreal, Quebec H3A 2K6, Canada
E-mail: tak-hang.chan@mcgill.ca

Key words: multiple myeloma, bortezomib, curcumin, curcumin analogs, drug resistance
potential as chemopreventive agents. Curcumin is one such compound that has attracted much interest due to its proven pharmacological safety and its many favorable biological activities such as anti-inflammation, anti-oxidation, chemopreventive and chemotherapeutic activities (8). Recently, the tumor cellular proteasome has been reported as an important target of curcumin (9).

The anticancer effects of curcumin, both alone and in combination with chemotherapeutics are widely supported by several studies (10-12). Curcumin in combination with bortezomib has been reported to synergistically induce apoptosis in human multiple myeloma U266 cells (13). Curcumin was reported to potentiate the effect of bortezomib against human multiple myeloma in a nude mice model (14). These observations therefore suggest that a superior therapeutic index may be achieved with curcumin when used in combination and could be advantageous in the treatment of refractory tumors.

Unfortunately, the in vivo biological activities of curcumin were found to be greatly reduced due to its low solubility and bioavailability in tissues remote from the gastrointestinal tract (10-12). In an effort to enhance the bioavailability of curcumin, we synthesized several novel analogs of curcumin, and we recently reported that water soluble amino acid conjugates of curcumin are potent proteasome inhibitors and showed a potent antiproliferative effect in several human cancer cell lines (15). Docking studies of these conjugates suggested that they may serve as the water soluble analogs of curcumin (15). In the present study, we examined the ability of the curcumin analogs 6-13 (Fig. 1) (15) to sensitize multiple myeloma cells to otherwise sublethal concentrations of bortezomib and enhance its proteasome-inhibitory anticancer activities.

Materials and methods

Cell culture. Human multiple myeloma Arp cell line, kindly provided by Dr Ramesh Batchu (Wayne State University), were grown in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. Cells were maintained at 37˚C in 5% CO₂.

Chemicals. Amino acid conjugates 6-13 of curcumin were prepared as previously reported (15).

Inhibition of purified 20S and cellular 26S proteasome activity by curcumin and its analogs. Arp multiple myeloma cells were treated with curcumin or amino acid conjugated water soluble curcumin analogs either alone or in combination with bortezomib for 48 h at 37˚C. All activities in both the purified proteasome and the cellular proteasome were measured following a previously described protocol (16).

Cell proliferation and viability. Myeloma cells were grown in 96-well plates. Cells were treated with the indicated concentrations of curcumin or the curcumin analogs alone or in combination with bortezomib for 24-48 h followed by an MTT assay to measure cell proliferation and cell viability (17).

Figure 1. Structures of (A) curcumin and (B-D) amino acid-conjugated curcumin analogs 6-13.

Immunoblotting. Multiple myeloma cells were treated with either curcumin or its analogs both alone and in combination with bortezomib at 5 nM concentration for 48 h. Cells were then harvested for the preparation of lysates. Equal amounts of protein (40 µg/lane) were electrophoresed on SDS-PAGE gels, transferred to nitrocellulose, and probed with the indicated antibodies as previously described (17).

Results

Curcumin analogs enhance the inhibitory effect of bortezomib on the purified 20S proteasome. To determine if the curcumin analogs could add to or inhibit bortezomib’s activity, the analogs alone or in combination with bortezomib were evaluated for their ability to inhibit the purified 20S proteasome CT activity. Curcumin analogs were examined at 2.5, 5 and 10 µM both alone and in combination with bortezomib (Vel) at 10 nM. Curcumin analogs 6, 7, 8 and 9 did not significantly inhibit CT-activity of purified 20S proteasome when compared with bortezomib. They did not add to or inhibit bortezomib activity in combination studies (data not shown). On the other hand, the water soluble analogs of curcumin 10, 11, 12 and 13 alone potently inhibited proteasomal CT activity (data not shown). When used in combination with 10 nM bortezomib the effect was additive and they further lowered the CT activity compared with bortezomib alone. The most pronounced effect was observed with analog #12 (Fig. 2). In particular, #12 at 10 µM in combination with bortezomib at
20 nM was appreciably more effective in suppressing CT-like activity than bortezomib at 20 nM alone. In comparison, curcumin at 10 µM in combination with bortezomib at 20 nM did not have a pronounced inhibitory effect under our experimental conditions.

**Curcumin analogs enhance the proteasome-inhibitory effect of bortezomib in human myeloma cells.** We next determined if the curcumin analogs could add to bortezomib’s activity in intact myeloma cells. Arp cells were co-treated with curcumin analogs 10, 11, 12 and 13 at 10 µM for 48 h both alone and in combination with bortezomib at 10 nM, and cell extracts were then prepared and assayed for three proteasomal activities (CT-, PGPH- and trypsin-like). None of the analogs alone at 10 µM could inhibit the activities of the proteasome in these cells (data not shown). Analog #12, but not curcumin, enhanced the effects of bortezomib and the co-treatment showed potent inhibitory effects on CT-, PGPH- and trypsin-like activities of the proteasome (Fig. 3A-C).

**Curcumin analogs enhance bortezomib-mediated proliferation inhibition and apoptosis induction in multiple myeloma cells.** We then determined whether the observed enhancement of the proteasome-inhibitory effect of bortezomib by the water soluble curcumin analog #12 was associated with an increase in the growth inhibition and apoptosis induction in these cells. Water soluble curcumin analogs were tested for inhibition of cell proliferation in ARP multiple myeloma cells by the MTT assay at various concentrations, (2.5, 5, and 10 µM) both alone and in combination with bortezomib at 5 and 10 nM. DMSO and curcumin were used as controls. Curcumin analogs 10, 11, 13 and especially 12 showed inhibition of cell proliferation but further inhibition was observed when they were combined with bortezomib at 5 and 10 nM (Fig. 4 and data not shown). In the cells co-treated with analog #12 and bortezomib (Fig. 3), caspase-3 activity was also enhanced (Fig. 3D). The combination of curcumin and bortezomib had no such enhancing effect. These results show that the sensitivity of Arp myeloma cells to cytotoxic killing in the presence of otherwise sublethal concentrations of bortezomib was enhanced by incubation with curcumin analog #12.

**Curcumin analog #12 increases cellular proteasome-inhibitory and apoptosis-inducing activity of bortezomib in a time-dependent manner.** To understand the mechanism of sensitization by the curcumin analog #12, we performed a
kinetic experiment using a combination of 10 µM of analog #12 and 5 nM bortezomib in Arp cells. Western blot analysis of the co-treatment revealed a time-dependent increase in the accumulation of ubiquitinylated proteins and the proteasome target protein p27 in co-treated cells compared with each treatment alone (Fig. 5). Compared with bortezomib treatment alone, co-treatment with analog #12 also increased PARP and caspase 3 cleavages at early time points (Fig. 5). These results suggest that analog #12 induced apoptosis in the presence of otherwise sublethal concentrations of bortezomib.

Discussion

Cancer treatment requires simultaneous suppression of multiple signaling/survival pathways. Therefore, emphasis has been laid on combinational therapies that may be more effective than single agents. Previously, curcumin has been reported to synergize with bortezomib and potentiate the apoptotic effects in human multiple myeloma U266 cells via down regulating NF-κB and its regulated gene products (13). We have previously reported that curcumin can potentially inhibit the proteasome activity which is required for the subsequent activation of the NF-κB pathway (9). Although curcumin is very effective, it is poorly water soluble and less bioavailable in tissues remote from the gastrointestinal tract. In our efforts to enhance its bioavailability we synthesized amino acid-conjugated curcumin analogs and have previously reported them to be potent inhibitors of the proteasome and cell proliferation (15). Based on our previous work with curcumin analogs we further investigated the efficacy of these analogs as chemosensitizers, in combination with bortezomib.

Consistent with our earlier observations in human colon cancer and prostate cancer cells, water soluble amino acid-conjugated curcumin analogs showed potent inhibition of the proteasome and cell proliferation in Arp multiple myeloma cells. Among the curcumin analogs, combination of analog #12 and bortezomib had a more additive effect on proteasome inhibition, proliferation inhibition, and apoptosis induction in these cells. To confirm that the additive effects of this analog were possibly through inhibition of the cellular proteasome activity in these cells we investigated the various proteasomal activities. Our results from the proteasomal activity assays indicate that analog #12 of curcumin when combined with bortezomib could extensively inhibit the CT-like, trypsin-like and PGPH-like activities of the cellular proteasome (Fig. 3). Furthermore, the combination of analog #12 with bortezomib results in a considerable increase in caspase activity. An increase in caspase-3 cleavage at earlier time points in the combination treatments could trigger apoptosis in these cells (Fig. 5).

In chemoresistant multiple myeloma cells from patients, the NF-κB pathway has been shown to be constitutively active compared with chemosensitive lines and has been associated with resistance to anticancer therapy (6). However, the activation of NF-κB has been shown to be prevented by proteasome inhibitors (18). Thus, in the ARP human MM cell line, our results suggest that analog #12 of curcumin could induce apoptosis in the presence of otherwise sublethal concentrations of bortezomib possibly through the down-regulation of the NF-κB pathway as a downstream effect of proteasome inhibition, which will be investigated in the near future. Therefore, it is possible that water soluble curcumin analog #12 with increased bioavailability may be useful as potential replacement of curcumin and could be used in combination to bortezomib. Validation of such possibility using animal models is warranted.

Acknowledgements

We thank Dr Ramesh Batchu (Wayne State University) for providing human multiple myeloma Arp cell line. This work was partially supported by grants from Karmanos Cancer Institute 2009 Pilot project funding (to Q.P.D) and the National
Cancer Institute (1R01CA120009, 3R01CA120009-04S1 and 5R01CA127258-05, to Q.P.D).

References

1. Oerlemans R, Franke NE, Assaraf YG, et al: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499, 2008.
2. Smith AJ, Dai H, Correia C, et al: Noxa/Bel-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286: 17682-17692, 2011.
3. Kern J, Untergasser G, Zenza C, et al: GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood 114: 3960-3967, 2009.
4. Shringarpure R, Catley L, Bhole D, et al: Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 134: 145-156, 2006.
5. Fournier MJ, Gareau C and Mazroui R: The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int 10: 12, 2010.
6. Yang DT, Young KH, Kahl BS, Markovina S and Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40, 2008.
7. Golden EB, Lam PY, Kardosh A, et al: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 113: 5927-5937, 2009.
8. Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
9. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP and Dou QP: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68: 7283-7292, 2008.